In the BioHarmony Drug Report Database

"Preview" Icon

Sacituzumab govitecan

Trodelvy (sacituzumab govitecan) is an antibody pharmaceutical. Sacituzumab govitecan was first approved as Trodelvy on 2020-04-22. It is used to treat triple negative breast neoplasms in the USA. The pharmaceutical is active against tumor-associated calcium signal transducer 2.

 

Trade Name

 

Trodelvy
 

Common Name

 

sacituzumab govitecan
 

ChEMBL ID

 

CHEMBL3545262
 

Indication

 

triple negative breast neoplasms
 

Drug Class

 

Monoclonal antibodies: humanized, tumors as target; antineoplastics (camptothecine derivatives)

Image (chem structure or protein)

Sacituzumab govitecan structure rendering